David Headley, MD
Family Medicine · Port Gibson, MSNPI 1528032406
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 142 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by GSK at 42.1% of the total. Reporting peaked in 2022 at $385 and has fallen 90.1% since, to $38 in 2025.
Across 142 payments — averaging $8.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$531
- AbbVie$105
- Teva Pharmaceuticals USA, Inc.$99
- GRT US Holding, Inc.$80
- Merck$66
- Novartis$53
- plus $328 from 15 others
Across 165 payments — averaging $3887.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$372K
- Novartis$165K
- Alnylam Pharmaceuticals Inc.$22K
- Chiesi USA, Inc.$22K
- Amgen$20K
- Novo Nordisk AS$14K
- plus $27K from 3 others
What the payments were for
- Food & beverage$1,263100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 98 | $531 |
| AbbVie | 5 | $105 |
| Teva Pharmaceuticals USA, Inc. | 6 | $99 |
| GRT US Holding, Inc. | 4 | $80 |
| Merck | 5 | $66 |
| Novartis | 3 | $53 |
| Novo Nordisk | 3 | $40 |
| SK Life Science, Inc. | 2 | $33 |
| Lundbeck LLC | 2 | $32 |
| Abbott | 2 | $31 |
| AstraZeneca | 2 | $28 |
| Vivus LLC | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Bioventus LLC | 1 | $17 |
| Pfizer | 1 | $17 |
| Bayer | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Amgen | 1 | $13 |
| Genentech USA, Inc. | 1 | $13 |
| Nabriva Therapeutics, PLC | 1 | $12 |
How this compares
$1,263 in reported general payments places this provider in the 60th percentile of 971 family medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 177 | $230,129 |
| OzempicSemaglutide | 206 | $218,707 |
| AustedoDeutetrabenazine | 23 | $162,170 |
| EliquisApixaban | 154 | $103,330 |
| JardianceEmpagliflozin | 128 | $93,257 |
| LinzessLinaclotide | 124 | $82,842 |
| XareltoRivaroxaban | 160 | $65,899 |
| JanuviaSitagliptin Phosphate | 100 | $49,264 |
| Invega SustennaPaliperidone Palmitate | 13 | $46,542 |
| FarxigaDapagliflozin Propanediol | 66 | $43,119 |
| ZenpepLipase/Protease/Amylase | 12 | $31,041 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $29,552 |
| EntrestoSacubitril/Valsartan | 37 | $23,848 |
| TradjentaLinagliptin | 33 | $23,330 |
| GlyxambiEmpagliflozin/Linagliptin | 16 | $13,443 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $40 | $218,707206 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $99 | $162,17023 claims |
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi | $16 | $130,029177 claims |
| PfizerEliquis, Abrysvo | $17 | $113,664187 claims |
| AbbVieLinzess | $105 | $82,842124 claims |
| MerckJanuvia, Janumet | $66 | $61,319118 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $28 | $53,12698 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $531 | $33,62148 claims |
| NovartisEntresto | $53 | $23,84837 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 971 family medicine providers in Mississippi.
Other family medicine in Port Gibson
- Russell CarlisleWesson$1.6M
- Keith StokesLexington$654K
- Walter CarnahanSouthaven$146K
- Karen WhitneyWhitfield$117K
- Dava ClevelandJackson$100K
- Andrea PhillipsJackson$96K
- Kristi TrimmRidgeland$34K
- Tana CooperBiloxi$25K
- Delora DenneyPicayune$24K
- Randall HulingOlive Branch$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.